• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CDKN1A Gene Record

  • Summary
  • Interactions
  • Claims
  • CDKN1A 1026 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    1026
    CYCLIN DEPENDENT KINASE INHIBITOR 1A
    CDKN1A
    CAP20
    CDKN1
    CIP1
    MDA-6
    P21
    SDI1
    WAF1
    p21CIP1
    116899
    1784
    ENSG00000124762
    OTTHUMG00000014603
    913
    PA104
    PIC1
    MDA6
    Cyclin-dependent kinase inhibitor 1
    P38936

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (6 More Sources)

    Gene Categories: Category Details

    TUMOR SUPPRESSOR
    KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
    Keshelava et al., 2001, Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines., Cancer Res.
    Yang et al., 2003, p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells., J. Clin. Endocrinol. Metab.
    Flamm et al., Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin., Anticancer Res.
    Lee et al., 2005, Effects of nicotine on proliferation, cell cycle, and differentiation in immortalized and malignant oral keratinocytes., J. Oral Pathol. Med.
    Sim et al., 2014, P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer., BMC Cancer
    de Angelis et al., 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil., Int. J. Oncol.
    Galmarini et al., 2003, Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine., Biochem. Pharmacol.
    Qiu et al., 1996, Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells., J. Biol. Chem.
    Qiu et al., 1997, The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells., Arch. Biochem. Biophys.
    Hsieh et al., 2000, Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase., Blood
    Pyrzynska et al., 2002, Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A., J. Biol. Chem.
    Tishler et al., 1996, The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1., Br. J. Cancer Suppl.
    Nguyen et al., 2004, Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells., Clin. Cancer Res.
    Lee et al., 2006, Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen., J. Pharmacol. Exp. Ther.
    Bott et al., 2005, p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation., Prostate Cancer Prostatic Dis.
    Xiang et al., 2002, Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors., Oncogene
    Wang et al., 2005, Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism., Asian J. Androl.
  • DIAZIQUONE   CDKN1A

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8943236


    Sources:
    NCI

  • PENTETIC ACID   CDKN1A

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9343371


    Sources:
    NCI

  • DEOXYCYTIDINE   CDKN1A

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16276353


    Sources:
    NCI

  • IRINOTECAN HYDROCHLORIDE   CDKN1A

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12032863


    Sources:
    NCI

  • DICUMAROL   CDKN1A

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9343371


    Sources:
    NCI

  • EPOETIN BETA   CDKN1A

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11023508


    Sources:
    NCI

  • CLADRIBINE   CDKN1A

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12473386


    Sources:
    NCI

  • FLUTAMIDE   CDKN1A

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16281084


    Sources:
    NCI

  • ROMIDEPSIN   CDKN1A

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15014036


    Sources:
    NCI

  • MELPHALAN   CDKN1A

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11507071


    Sources:
    NCI

  • VINBLASTINE   CDKN1A

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8763853


    Sources:
    NCI

  • ACETAMINOPHEN   CDKN1A

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16330492


    Sources:
    NCI

  • NICOTINE   CDKN1A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16011614


    Sources:
    NCI

  • FLUOROURACIL   CDKN1A

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24708484 15067352


    Sources:
    NCI CIViC

  • CYCLOSPORINE   CDKN1A

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11827957


    Sources:
    NCI

  • CELECOXIB   CDKN1A

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22336956


    Sources:
    PharmGKB

  • CARBOPLATIN   CDKN1A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12168940


    Sources:
    NCI

  • PACLITAXEL   CDKN1A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12574211


    Sources:
    NCI

  • Ensembl: ENSG00000124762

    • Version: 101_38

    Alternate Names:
    CDKN1A Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: CDKN1A

    • Version: 18-August-2020

    Alternate Names:
    PA104 PharmGKB ID

    Gene Info:

    Publications:
    Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

  • CIViC: CDKN1A

    • Version: 14-September-2020

    Alternate Names:
    1026 Entrez Gene ID
    913 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Sim et al., 2014, P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer., BMC Cancer

  • NCI: CDKN1A

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Lee et al., 2005, Effects of nicotine on proliferation, cell cycle, and differentiation in immortalized and malignant oral keratinocytes., J. Oral Pathol. Med.
    de Angelis et al., 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil., Int. J. Oncol.
    Qiu et al., 1997, The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells., Arch. Biochem. Biophys.

  • HingoraniCasas: ENSG00000124762

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000124762 Gene Symbol
    CDKN1A Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: CDKN1A

    • Version: 01-February-2022

    Alternate Names:
    CAP20 GO Gene Synonym
    CDKN1 GO Gene Synonym
    CIP1 GO Gene Synonym

    Gene Info:

    Gene Categories:
    TUMOR SUPPRESSOR

    Publications:

  • Tempus: CDKN1A

    • Version: 11-November-2018

    Alternate Names:
    CDKN1A Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Pharos: CDKN1A

    • Version: 01-February-2022

    Alternate Names:
    Cyclin-dependent kinase inhibitor 1 Gene Name
    P38936 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • MskImpact: CDKN1A

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: CDKN1A

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21